World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
55498
World Ranking
9080
National Ranking
4683

Overview

Siraj M. Ali is affiliated with Foundation Medicine in the United States. Their research spans primarily the fields of Medicine and Biochemistry, Genetics and Molecular Biology, contributing to a significant body of scientific literature.

Their work engages multiple subfields including Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Surgery, and Cancer Research. This diverse expertise reflects a focus on various aspects of cancer biology and therapeutic strategies.

Main research topics addressed by Siraj M. Ali include:

  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Radiomics and Machine Learning in Medical Imaging
  • Bladder and Urothelial Cancer Treatments
  • Epigenetics and DNA Methylation
  • Cancer Immunotherapy and Biomarkers
  • Prostate Cancer Treatment and Research

The scientist's notable publications cover critical advancements in oncology and genomic profiling. Significant papers include:

  • AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations, 2022, Journal of Clinical Oncology
  • Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity, 2020, JCO Precision Oncology
  • Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma, 2022, Nature Communications
  • Clinicopathologic Characteristics of BRG1-Deficient NSCLC, 2020, Journal of Thoracic Oncology
  • Truncated FGFR2 is a clinically actionable oncogene in multiple cancers, 2022, Nature

Siraj M. Ali frequently collaborates with a number of researchers, including:

  • Jeffrey S. Ross
  • Russell W. Madison
  • Vincent A. Miller
  • Brian M. Alexander
  • Chan-Young Ock

Publications by Siraj M. Ali are commonly found in several key scientific venues, reflecting both clinical and research-oriented audiences. Frequent publication venues include:

  • Journal of Clinical Oncology
  • The Oncologist
  • Regular and Young Investigator Award Abstracts
  • JCO Precision Oncology
  • Cancer Research

Best Publications

  • mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

    Do Hyung Kim;Dos D. Sarbassov;Siraj M. Ali;Jessie E. King

  • Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

    Dos D. Sarbassov;Siraj M Ali;Do-Hyung Kim;David A Guertin

  • Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

    Dos D. Sarbassov;Siraj M. Ali;Siraj M. Ali;Shomit Sengupta;Shomit Sengupta;Joon Ho Sheen;Joon Ho Sheen

  • Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

    Zachary R. Chalmers;Caitlin F. Connelly;David Fabrizio

  • Growing roles for the mTOR pathway

    Dos D Sarbassov;Siraj M Ali;David M Sabatini

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • GβL, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR

    Do Hyung Kim;Dos D. Sarbassov;Siraj M. Ali;Robert R. Latek

  • Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

    Garrett M. Frampton;Siraj M. Ali;Mark Rosenzweig;Juliann Chmielecki

  • Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux

    Andrew M. Cameron;Joseph P. Steiner;A.Jane Roskams;Siraj M. Ali

  • Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study

    Andrea Necchi;Andrea Anichini;Daniele Raggi;Alberto Briganti

  • Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

    A.B. Schrock;C. Ouyang;C. Ouyang;J. Sandhu;E. Sokol

  • New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

    Jeffrey S. Ross;Jeffrey S. Ross;Kai Wang;Rami Al-Rohil

  • Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

    Douglas B. Johnson;Garrett M. Frampton;Matthew J. Rioth;Erik Yusko

  • Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

    Eli L. Diamond;Benjamin H. Durham;Julien Haroche;Zhan Yao

  • Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

    Janice M. Mehnert;Anshuman Panda;Hua Zhong;Hua Zhong;Kim Hirshfield

  • Biliary cancer: Utility of next-generation sequencing for clinical management.

    Milind Javle;Tanios Bekaii-Saab;Apurva Jain;Ying Wang

  • Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

    Alexa B. Schrock;Garrett M. Frampton;James Suh;Zachary R. Chalmers

  • Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer

    Jeremy C. Jones;Lindsay A. Renfro;Humaid O. Al-Shamsi;Alexa B. Schrock

  • The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

    Jeffrey S. Ross;Kai Wang;Juliann Chmielecki

  • Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.

    Sun Min Lim;Hye Ryun Kim;Jong-Seok Lee;Ki Hyeong Lee

Frequent Co-Authors

Jeffrey S. Ross
Jeffrey S. Ross Foundation Medicine
Philip J. Stephens
Philip J. Stephens Foundation Medicine
Garrett M. Frampton
Garrett M. Frampton Foundation Medicine
Sai-Hong Ignatius Ou
Sai-Hong Ignatius Ou University of California, Irvine
Shridar Ganesan
Shridar Ganesan Rutgers, The State University of New Jersey
Brian M. Alexander
Brian M. Alexander Foundation Medicine
Nir Peled
Nir Peled Hebrew University of Jerusalem
Toni K. Choueiri
Toni K. Choueiri Harvard University
Jeeyun Lee
Jeeyun Lee Sungkyunkwan University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine, there are several online degree options that can complement or offer alternative pathways within the healthcare sector. From administration to pharmacy to advanced nursing, these programs can help you achieve your goals with greater flexibility.

For those interested in healthcare leadership, online mha programs affordable offer a cost-effective way to earn a master's in healthcare administration. This degree prepares graduates for management and executive roles in hospitals, clinics, and health systems.

Aspiring advanced practice nurses can explore best online bsn to dnp programs, which allow registered nurses to earn a Doctor of Nursing Practice (DNP) online, expanding their clinical and leadership opportunities.

For those drawn to pharmacy, earning an online pharmacy degree can open doors to patient care, research, and medication management. These programs offer the convenience of studying remotely while preparing for licensure.

Finally, if you’re interested in the intersection of healthcare and technology, online schools for health information management can lead to roles overseeing vital patient data and health informatics systems.

Best Scientists Citing Siraj M. Ali

Trending Scientists

Recently Published Articles